NRAS and colorectal carcinoma: To clarify whether NRAS‐mutation(+) CRC constitutes a unique CRC subtype occurring through distinct tumorigenic pathway, further analyses should be performed, including comprehensive analyses of genomic and epigenomic aberrations in precancerous NRAS‐mutation(+) colorectal lesions, for example, aberrant crypt foci and adenoma as well as NRAS‐mutation(+) CRC.